Positive Results From Multi-Centre, Prospective Clinical Trial for Diagnosis of Basal Cell Carcinoma Using Michelson Diagnostics’ VivoSight OCT Presented at AAD

March 21, 2014

ORPINGTON, England, March 21, 2014 /PRNewswire/ –

Michelson Diagnostics, the UK based medical device company focused on multi-beam
Optical Coherence Tomography (‘OCT’) technology, today announces positive results from the
successfully completed multi-centre, prospective clinical trial for the diagnosis of basal
cell carcinoma using VivoSight OCT to be presented at the upcoming American Academy of
Dermatology’s 72nd Annual Meeting (AAD) in Denver, Colorado, 21-25 March 2014.

Papers by Professor Dr. med. Julia Welzel, Dr. med. Martina Ulrich discussing results
from the clinical study will be presented in the AAD Conference Session F153 “Non-Invasive
Imaging in Dermatology” on Tuesday, 25 March at 1.00pm.

The presented results support Michelson Diagnostics vision that its VivoSight OCT
system has the potential to become the standard of care for the non-invasive diagnosis and
monitoring of certain diseases and conditions that affect the skin, and in particular
non-melanoma skin cancer. For further information come and meet the team at the Michelson
Diagnostics booth, number 2255 -


The AAD Annual Meeting is the largest dermatology meeting in the world, with
approximately 20,000 delegates expected from more than 90 countries. The AAD supports the
highest-quality patient care by developing and presenting information that enhances
continuing education in dermatology. AAD meetings offer the latest on the diagnosis,
prevention, and treatment of dermatologic disease from the foremost experts in the field.

All abstracts and details on timings can be accessed through the AAD website:


The title, timing and location of the poster presentations are as follows:

        Abstract         F153
        Title:           Non-Invasive Imaging in Dermatology
                         Orit Markowitz, MD, FAAD; Robert Bard, MD; Theresa Cao, DO;
                         Gerald Messer; Daniel M. Siegel, MD, MS, FAAD ; Dan Sperling,
        Authors:         MD; Martina Ulrich, MD; Julia Welzel, MD
                         This forum will address the utility of some of the most
                         recent dermatologic non-invasive imaging devices including
                         optical coherence tomography, the new handheld confocal
                         microscope, 3-D high resolution ultrasound, MRI as well as
                         MRI/US fusion. The attendee will be able to recognize basic
                         images with these devices, how they differ and understand
                         what role each plays in daily practice as well as in basic
                         dermatologic research. The most recent imaging advances
                         ranging from measuring in transit melanoma metastases,
                         visualization of field cancerization, monitoring non-invasive
                         treatment of skin cancer and even diagnosis of onychomycosis
        Session Info:    will be discussed.
        Day/Date:        Tuesday 25 March 2014
        Session Time:    1pm - 3pm Eastern Time
        Location :       Room 705/707

For further information

Notes to editors

About Michelson Diagnostics and the VivoSight System

Michelson Diagnostics has developed a world-leading, patented, medical imaging
technology, known as multi-beam Optical Coherence Tomography (‘OCT’), that uses an
advanced laser scanner to ‘see’ into tissue with unprecedented image resolution and
quality of image. Multi-beam OCT has many potential clinical applications, but we are
currently focusing on dermatology.

Our vision is for our VivoSight OCT system to become the standard of care for the
non-invasive diagnosis and monitoring of certain diseases and conditions that affect
cutaneous and epithelial linings of the body. We currently generate revenues from our
first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin
cancer (NMSC).

VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained
clinicians in their assessment of the patient’s medical condition. We have launched
VivoSight in Germany where the VivoSight scan is reimbursed for patients with private
healthcare insurance.

The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees. It
has sales offices in Germany and USA. It has been supported through funding from a
syndicate of Venture Capital, corporate and private investors including Octopus, Catapult
Ventures and Angel Investors.

For more information about Michael Diagnostics, see


        Michelson Diagnostics
        Tel: +44(0)20-8308-1695
        Jon Holmes, Chief Executive Officer

        FTI Consulting
        Tel: +44(0)20-7831-3113
        Simon Conway / Mo Noonan / Victoria Foster Mitchell

SOURCE Michelson Diagnostics

Source: PR Newswire

comments powered by Disqus